Piperazine Erastin

Research use only, not for human use.

Piperazine Erastin is an analog of Erastin, which can induces ferroptosis in cancer cells, an iron-dependent form of nonapoptotic cell death.

Piperazine Erastin is an analog of Erastin, which can induces ferroptosis in cancer cells, an iron-dependent form of nonapoptotic cell death.

Erastin is a ferroptosis activator. It triggers a unique iron-dependent form of non-apoptotic cell death that is termed as ferroptosis. Piperazine erastin is a more effective analog of erastin which is more water-soluble (0.086 mM for erastin versus 1.4 mM for piperazine erastin) and more metabolically stable. Piperazine erastin is affected similarly by cell death modulators as erastin and displays a distinct pattern from other non-FIN lethal compounds.

In the xenograft mouse model, a significant delay in tumor growth is observed in the piperazine erastin-treated group compared to the vehicle-treated group. Ptgs2 is upregulated in mouse liver with 10 or 60 mg/kg piperazine erastin administration.

Piperazine-Erastin | Piperazine Erastin | PiperazineErastin

Apoptosis

Ferroptosis

Ferroptosis

——

——

1538593-71-3

645.19084

C35H41ClN6O4

>98% (HPLC)

10 mM in DMSO

O=C1N(C2=CC(CN3CCNCC3)=CC=C2OC(C)C)C(CN4CCN(C(COC5=CC=C(Cl)C=C5)=O)CC4)=NC6=C1C=CC=C6

4(3H)-Quinazolinone, 2-[[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]methyl]-3-[2-(1-methylethoxy)-5-(1-piperazinylmethyl)phenyl]-

(-20℃)

With Ice Pack

≥ 2 years